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Abstract
Background: Lipids, which are associated with atherogenesis, clotting, and the fibrinolytic pathway, may be
important prognostic indicators of recurrent myocardial infarction. The aim of this study was to determine the
predictive value of baseline lipid fractions for nonfatal recurrent myocardial infarction in patients with ST segment
elevation myocardial infarction 2 years after primary percutaneous coronary intervention in China.
Methods: Cox proportional-hazards models were used to evaluate the association between potential risk factors,
including lipid fractions, and the occurrence of nonfatal recurrent myocardial infarction in 2402 consecutive patients
who underwent primary percutaneous coronary intervention for ST segment elevation myocardial infarction.
Results: The cumulative incidence of recurrent myocardial infarction was 2.7% at 1 year, 3.8% at 2 years, and 5.8%
at 3 years after percutaneous coronary intervention. The effects of collinearity of lipids were investigated. In
concerning the principal components analysis, composing factor 1 (scoring factors were 0.689 for non-HDL, 0.702
for LDL, 0.182 for HDL) which had eigenvalues of 1.86 and explained 62% of the variability among lipid cholesterols
was significantly associated with recurrent MI in the final adjusted analysis of the lipid cholesterols principal
components. Non-high-density lipoprotein cholesterol was the strongest independent predictor of nonfatal
recurrent myocardial infarction. The adjusted hazards ratios for nonfatal recurrent myocardial infarction were 1.26
(95% confidence interval (CI): 1.05–1.51) for non-high-density lipoprotein cholesterol, 1.17 (95% CI: 0.99–1.39) for
low-density lipoprotein and 1.15 (95% CI: 0.95–1.40) for HDL. After adjusting for gender and age, the odds ratio for
patients in the highest non-high-density lipoprotein cholesterol quartile was 2.10 (95% CI: 1.19–3.72).
Conclusions: Non-high-density lipoprotein cholesterol value is a stronger predictor of nonfatal recurrent myocardial
infarction than other lipid risk factors in patients with ST segment elevation myocardial infarction. Moreover, the
occurrence of reinfarction after percutaneous coronary intervention was highest for patients in the highest non-
high-density lipoprotein cholesterol quartile.
Trial registration: http://www.chictr.org.cn/edit.aspx?pid=13583&htm=4, registration number: ChiCTR-EPC-
16008199, date of registration:2013.01.01.
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Background
Primary percutaneous coronary intervention (PCI), the
current standard treatment for ST segment elevation myo-
cardial infarction (STEMI), reduces the risk of recurrent
myocardial infarction (MI). However, MI reoccurs in 2–6%
patients after successful PCI and is associated with poor
clinical outcomes [1–3]. Survivors of acute coronary syn-
dromes have a high risk of recurrent events [4], the reasons
for which are complex and multifaceted. For instance, stent
thrombosis can lead to recurrent MI, although newer dur-
able polymer-based drug-eluting stents have antithrombo-
genic properties, resulting in a lesser degree of thrombus
adhesion [5–7]. Other events that can lead to recurrent MI
are the progression of atherosclerosis and lipid-rich plaque
rupture [4, 8, 9].
Lipids, which are associated with atherogenesis, clot-
ting, and the fibrinolytic pathway, are important prog-
nostic indicators of recurrent MI [8, 10]. Low-density
lipoprotein (LDL) cholesterol is a key risk factor for car-
diovascular disease, and current guidelines indicate that
first-line therapy should focus on lowering LDL [11–13].
However, prospective cohort studies show that non-
high-density lipoprotein (non-HDL) cholesterol is an in-
dependent risk factor for mortality among individuals
predominately free of coronary heart disease [14, 15],
and recently revised National Cholesterol Education
Program guidelines recommend that non-HDL and LDL
be equally targeted in patients with coronary heart dis-
ease [16]. Non-HDL, which is calculated by subtracting
high-density lipoprotein (HDL) cholesterol from total
cholesterol (TC) [13], includes triglyceride (TG)-rich
lipoprotein, LDL, very low-density lipoprotein (VLDL),
chylomicron remnants, and intermediate-density lipo-
protein (IDL) [17, 18].
Recently, Non-HDL has arose considerable interest and
been shown to be an effective predictor of cardiovascular
disease, including cardiovascular mortality, in patients
with [19–21] and without [15, 22, 23] cardiovascular dis-
ease. However, few studies have explored the predictive
value of non-HDL after adjusting for collinearity among
lipid variables and directly compared varying baseline lipid
fractions for predicting nonfatal recurrent MI for coronary
artery stenosis among patients with STEMI treated with
stents or angioplasty, especially in China. In China, home
to one-fifth of the world’s people, there is a rising burden
of cardiovascular disease. Therefore, previously studies
from Western countries may not be applicable. It is
known, racial differences, including genetic factors, life
style, and the environmental circumstances will affect
long-term outcomes in STEMI patients. Consequently,
the aim of this study was to determine whether baseline
TG, HDL, non-HDL, or LDL values predict nonfatal re-




Data were analyzed from patients with a first STEMI who
were admitted to the cardiology department at the First
Hospital of Jilin University between January 1, 2013 and
December 31, 2014. In accordance with the European So-
ciety of Cardiology/American College of Cardiology con-
sensus document [24], we included patients who met at
least two of the following criteria: characteristic severe
chest pain lasting more than 30 min, electrocardiographic
changes, and/or elevation of serum cardiac biomarkers.
We excluded patients who had a previous MI, were cur-
rently receiving lipid-lowering treatment or drugs, or had
insufficient baseline lipid measurement. In total, we in-
cluded 2402 consecutive STEMI patients who underwent
PCI without thrombolysis or conservative therapy. Base-
line demographic data, medical history, laboratory data,
angiographic results, and clinical variables during
hospitalization were retrieved from the department’s elec-
tronic database (Table 1). The study protocol was ap-
proved by the ethics review board of the First Hospital of
Jilin University (No. 2016–263).
Primary PCI protocol
Before PCI, patients were administered aspirin (loading
dose of 300 mg and maintenance dose of 100 mg/day),
clopidogrel (loading dose of 600 mg and maintenance
dose of 75 mg/day), and intravenous unfractionated hep-
arin (70 U/kg bolus). Coronary angiography was per-
formed using standard techniques. Thrombus aspiration,
a temporary pacemaker, and/or an intra-aortic balloon
pump were used at the surgeon’s discretion. Standard
management was provided by responsible physicians.
Generally, patients received aspirin, atorvastatin/rosu-
vastatin, clopidogrel, a β-blocker, angiotensin-converting
enzyme inhibitors/angiotensin II receptor blockers and
diuretics. Dural antiplatelet therapy was prescribed for at
least 1 year in all patients with successful drug-eluting
stents implantation.
Biochemical analysis
Baseline TC, TG, HDL, glucose, and LDL values were
measured directly in plasma after fasting. All blood sam-
ples were obtained at the time of hospital admission and
were analyzed in the certified laboratory department of
the First Hospital of Jilin University.
Clinical follow-up
A diagnosis of recurrent MI required two of the follow-
ing criteria: ischemic symptoms for at least 30 min, elec-
trocardiographic changes and creatine kinase-MB value
at least twice the upper limit of normal, or troponin I
value at least twice the upper limit of normal. Troponin
I levels were not used to diagnose recurrent MI within
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10 days of the index MI. Follow-up data were collected
from hospital records and telephone interviews after dis-
charge until death or April 1, 2016, whichever occurred
first. Mortality data for patients who were lost to tele-
phone follow-up were obtained from computerized re-
cords of the population registry bureau.
Statistical analysis
Continuous variables are presented as mean ± standard
deviation (SD), and categorical variables are presented
as frequency and percentage. Baseline continuous and
categorical variables for patients with and without re-
current MI during follow-up were compared using Wil-
coxon’s rank-sum tests and Chi-square tests,
respectively. Cox proportional hazard models were used
to evaluate associations between baseline lipid levels
and clinical characteristics and recurrent MI at 2-year
follow-up. Potential confounding factors were entered
into the multivariate predictors of recurrent MI if they
were clinical relevant or showed univariate differences
between groups. Included confounders were lipid, in-
farct location, diabetes mellitus, atrial fibrillation, per-
ipheral vascular disease, method of reperfusion,
thrombus aspiration, temporary pacemaker and num-
ber of stents. The lipid variables were correlated in
multivariate analysis and potentially resulting in multi-
collinearity. Principle component analysis was per-
formed in order to investigate the effects of collinearity
expected to occur among lipid cholesterol and to deter-
mine weights for the included variables. The variables
which contributed most to the variance were then se-
lected to be included in the regression analysis. Multi-
variate models were constructed for lipid risk factor
Table 1 Baseline characteristics of participants
Characteristic Recurrent MI P-value
Yes (n = 103)
n (%) or
mean ± SD




Age (years) 58 ± 12 59 ± 11 0.817
Male 69 (67.0) 1642 (71.4) 0.331
Hospital stay (days) 6.9 ± 2.9 7.2 ± 3.5 0.946
Medical history
Diabetes mellitus 45 (43.7) 1044 (45.4) 0.152
Hypertension 29 (28.2) 509 (22.1) 0.731
Previous PCI 3 (2.9) 66 (2.9) 0.980
Atrial fibrillation 1 (1.0) 90 (3.9) 0.126
Peripheral vascular disease 3 (2.9) 35 (1.5) 0.261
Arrhythmia (VT/VF) 9 (8.7) 166 (7.2) 0.562
Infarct location by ECG 0.032
Inferior 38 (36.9) 1114 (48.5)
Anterior 60 (58.3) 1131 (49.2)
Lateral 5 (4.9) 54 (2.4)
Killip classification 0.925
I 82 (79.6) 1796 (78.1)
II 14 (13.6) 312 (13.6)
III 3 (2.9) 66 (2.9)
IV 4 (3.9) 125 (5.4)
Laboratory data
K+ (mmol/L) 3.9 ± 0.5 3.9 ± 0.5 0.181
Na+ (mmol/L) 138.6 ± 5.8 139.2 ± 4.1 0.685
Non-HDL (mmol/L) 3.8 ± 1.2 3.5 ± 1.0 0.003
HDL (mmol/L) 1.2 ± 0.3 1.1 ± 0.3 0.053
LDL (mmol/L) 3.1 ± 1.0 2.8 ± 0.8 0.004
TG (mmol/L) 1.8 ± 1.1 1.7 ± 1.2 0.309
Glucose (mmol/L) 7.6 ± 3.2 7.4 ± 3.3 0.368
ALT (unit/L) 46.4 ± 33.1 58.4 ± 114.4 0.171
AST (unit/L) 162.2 ± 162.9 176.4 ± 297.3 0.932
Alkaline phosphatase
(unit/L)
71.1 ± 23.1 73.6 ± 28.1 0.309
ɤ-Glutamyl transpeptidase
(unit/L)
46.8 ± 43.3 49.1 ± 73.8 0.980
Cardiac troponin I (ng/mL) 23.4 ± 67.7 22.2 ± 62.0 0.646
Creatine kinase MB (ng/ml) 31.7 ± 53.4 40.8 ± 77.7 0.415
NT-proBNP (pg/mL) 1595.7 ± 2259.3 1889.2 ± 4908.0 0.967
Number of stents 1.2 (0.8) 1.2 (0.8) 0.605
Method of reperfusion 0.046
Balloon angioplasty 18 (17.5) 255 (11.1)
Drug-eluting stent
implantation
85 (82.5) 2044 (88.9)
Thrombus aspiration 9 (8.7) 280 (12.2) 0.294
Table 1 Baseline characteristics of participants (Continued)
Temporary pacemaker 3 (2.9) 137 (6.0) 0.197
Late PCI (>12 h after
symptom onset)
65 (63.1) 1352 (58.8) 0.386
Discharge medications
Aspirin 100(97.1) 2263(98.4) 0.290
Platelet P2Y12 inhibitor 69(67.0) 1502(65.3) 0.729
Statins 101(98.1) 2276(99.0) 0.357
Beta-blocker 71(68.9) 1477(64.3) 0.331
ACE inhibitor or ARB 68(66.0) 1317(57.3) 0.079
Calcium blockers 6(5.8) 128(5.6) 0.911
Diuretic 34(33.0) 750(32.6) 0.935
All-cause mortality at
2 years
7 (6.8) 119 (5.2) 0.471
SD standard deviation, PCI percutaneous coronary intervention, VT/VF
ventricular tachycardia/fibrillation, ECG electrocardiogram, non-HDL non-high-
density lipoprotein, HDL high-density lipoprotein, LDL low-density lipoprotein,
ALT alanine aminotransferase, AST aspartate aminotransferase, NT-proBNP N-
terminal pro-brain natriuretic peptide, ACE angiotensin-converting enzyme,
ARB angiotensin receptor blocker
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adjusting for other predictors in univariate analyses to
calculate multiple-adjusted Hazard ratios (HRs) and
their 95% confidence intervals (CIs). According to com-
mon practice in principal component analysis, principal
composing factors 1 and 2 were retained as covariates
in the multivariate models of recurrent MI. Regression
coefficients were calculated to estimate the HRs associ-
ated with 1-SD higher baseline values of each baseline
lipid fraction: 1.20 mmol/L TG, 1.03 mmol/L non-HDL,
0.83 mmol/L LDL, and 0.30 mmol/L HDL. Model 1
was adjusted for age and gender, and model 2 was ad-
justed for age, gender, Killip classification, prior PCI,
diabetes mellitus, hypertension, stroke, atrial fibrilla-
tion, thrombus aspiration, arrhythmia (ventricular
tachycardia/fibrillation (VT/VF)), and method of reper-
fusion. Model 3 was with variables in Model 2, as well
as with additional lipid fraction (per SD change) of
non-collinearity. Lipid values were categorized into
quartiles (≤25th, 25th to <50th, 50th to <75th, and
≥75th percentiles). Patients with lipid values in the low-
est quartile were used as a reference to assess associa-
tions between lipid fractions and recurrent MI,
adjusting for covariates. For all analyses, a two-sided P-
value <0.05 was considered statistically significant. All
analyses were conducted using Stata software, version
12 (Stata Corp., College Station, TX).
Results
Incidence of nonfatal recurrent MI
Of the 2402 patients included in this study, there
were 129 deaths during the median 2.2 years of
follow-up (range: 30–1226 days). A total of 102 pa-
tients suffered recurrent nonfatal MI. The incidence
of recurrent MI was 2.7% at 1 year, 3.8% at 2 years,
and 5.8% at 3 years (Fig. 1).
Risk factors for recurrent MI
Baseline data from patients with and without recurrent
MI, including demographic characteristics, medical his-
tory, laboratory data, culprit vessel, and PCI procedure,
are shown in Table 1. In concerning the principal compo-
nents analysis, composing factor 1 had eigenvalues of 1.86
and explained 62% of the variability among lipid choles-
terols and composing factor 2 had eigenvalues of 0.98 and
explained 33%. Table 2 presented the scoring factors for
each variable composing factor 1 and 2. Composing factor
1 was significantly associated with recurrent MI in the
final adjusted analysis of the lipid cholesterols principal
components (Table 3). Compared with patients without
recurrent MI, patients with recurrent MI had significantly
higher non-HDL and LDL values.
Patients with anterior MI, as detected by electrocar-
diogram (ECG), had a significantly higher rate of MI re-
currence than those with inferior or lateral MI. The
method of reperfusion also differed significantly between
patients with and without recurrent MI. Reinfarction
rates did not differ by gender or age. No associations
were observed between recurrent MI and diabetes melli-
tus, hypertension, previous PCI, atrial fibrillation, per-
ipheral vascular disease, arrhythmia (VT/VF), Killip
classification, number of stents, thrombus aspiration,
late PCI (>12 h after symptom onset), a temporary pace-
maker or discharge medications. Multivariate analysis
showed that lipid cholesterols, infarct location by ECG,
and successful drug-eluting stent implantation were sig-
nificant independent baseline predictors of nonfatal re-
current MI at 2-year follow-up (Table 3).
Lipid stratification and recurrent MI
Multivariate regression models examining baseline lipid
risk factors showed that nonfatal recurrent MI was most
strongly associated with non-HDL followed by LDL
(Table 4) after adjusting for age and gender (model 1) or
diabetes mellitus, hypertension, infarct location, method
of reperfusion, previous PCI, atrial fibrillation, arrhythmia
(ventricular tachycardia/fibrillation), Killip classification,
and thrombus aspiration (model 2) and variable in model
2 as well as with additional lipid fractions (per SD change)
of non-collinearity (model 3).
In the Adult Treatment Panel III report of the National
Cholesterol Education Program [13], non-HDL as a
Fig. 1 Incidence of recurrent MI during long-term follow-up. The in-
cidence of recurrent MI was 2.7% at 1 year, 3.8% at 2 years, and 5.8%
at 3 years
Table 2 Scoring factors for principle components
Variable Scoring factor




non-HDL non-high-density lipoprotein, LDL low-density lipoprotein
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secondary target should be limited to patients with elevated
serum TG values (>200 mg/dl). When our analysis was re-
stricted to patients with TG values ≤200 mg/dl, the adjusted
ORs were 1.49 (95% CI: 0.83–2.70) for non-HDL and 0.88
(95% CI: 0.45–1.72) for LDL. Thus, non-HDL was a stron-
ger predictor of nonfatal recurrent MI than other lipid risk
factors in all models.
We further categorized lipid values into quartiles
(Fig. 2, Additional file 1: Table S1). Patients in the high-
est non-HDL quartile had the highest OR for recurrent
MI in both univariate and multivariate models. Similar
results were observed for LDL quartiles, whereas no as-
sociations were found between HDL and TG values and
risk of recurrent MI. Furthermore, there was a linear in-
crease in the log OR for recurrent MI with increasing
non-HDL and LDL quartiles, suggesting a linear rela-
tionship between non-HDL and LDL values and recur-
rent MI.
Discussion
Within this cohort analysis of STEMI patients with baseline
lipid measurements, lipid cholesterols were an independent
predictor of nonfatal recurrent MI during long-term
follow-up after PCI in China, even when controlling for
several demographic and clinical variables known to influ-
ence patient outcome. The occurrence of reinfarction was
highest for patients with STEMI undergoing primary PCI
in the highest non-HDL cholesterol quartile and non-HDL
independently predicted nonfatal recurrent MI in a dose-
dependent manner.
Incidence of recurrent MI and prognostic implication
The 1-year MI recurrence rate for our patients was
lower than that previously reported for patients with
acute MI treated with primary PCI (6%) [25]. However,
in a meta-analysis of 23 trials, including patients with
STEMI who underwent primary angioplasty, the 1-year
MI recurrence rate was 3%, which is closer to our find-
ings [26]. Our results also support an increasing risk of
recurrent MI over time, with an incidence 2.15 times
higher at 3 years than at 1 year after the index MI. Al-
though MI recurrence rates vary among studies employ-
ing different definitions, sample sizes, and follow-up
periods, our results are consistent with those of previous
studies indicating that the risk of recurrent MI is not
eliminated after PCI despite rapid advances in percutan-
eous therapy over the past decades due to improvements
in stent platforms and implantation techniques, reduc-
tions in stent thrombosis, and the use of adjunctive
medical therapy [27–30]. However, prior studies had
demonstrated the superiority of stent implantation over
balloon angioplasty alone in the treatment of acute MI
[31–33]. Especially, drug-eluting stents further decreased
repeat revascularization of target lesion or stent throm-
bosis and target-vascular infarction than bare-metal
stents in patients with STEMI [28, 30]. Our results were
consistent with those of others. We found that success-
ful drug-eluting stent implantation reduced the risk of
recurrent MI compared with balloon angioplasty alone,
as patients with balloon angioplasty alone usually had
complicated or irregular coronary lumen or diffuse ath-
erosclerotic lesions [33].
Baseline lipid values and nonfatal recurrent MI
We found that non-HDL value was an independent pre-
dictor of nonfatal recurrent MI in patients with STEMI
after PCI. In comparing with other lipid fractions, non-
HDL value reflects the TG-rich lipoprotein content of
Table 3 Predictors of recurrent MI
Category Multivariate Analysis
Adjusted HR 95% CI P-value
Composing Factor 1 1.19 1.05–1.35 0.008
Composing Factor 2 1.13 0.94–1.36 0.202
Age 1.00 0.98–1.01 0.585
Gender 0.81 0.52–1.26 0.356
Infarct location by ECG 1.48 1.04–2.11 0.031
Diabetes mellitus 1.45 0.93–2.24 0.100
Atrial fibrillation 0.28 0.04–2.01 0.204
Peripheral vascular disease 1.94 0.60–6.21 0.266
Method of reperfusion 0.45 0.23–0.88 0.020
Thrombus aspiration 0.81 0.40–1.64 0.559
Temporary pacemaker 0.70 0.21–2.31 0.554
Number of stents 1.15 0.86–1.55 0.344
HR hazard ratio, CI confidential interval, non-HDL non-high-density lipoprotein,
LDL low-density lipoprotein. ECG electrocardiogram








Non-HDL 1.27 (1.08–1.50) 0.032 1.26 (1.06–1.49) 0.005 1.26 (1.05–1.51) 0.006
LDL 1.22 (1.03–1.44) 0.087 1.20 (1.02–1.42) 0.010 1.17 (0.99–1.39) 0.013
HDL 1.17 (1.00–1.40) 0.175 1.18 (0.99–1.40) 0.016 1.15 (0.95–1.40) 0.006
HR hazards radio, CI confidence interval, non-HDL non-high-density lipoprotein cholesterol, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein
cholesterol, TG triglyceride. Adjusted HRs with 95% CIs of lipid fraction per SD change (1.20 mmol/L TG, 1.03 mmol/L non-HDL, 0.83 mmol/L LDL, 0.30 mmol/L
HDL) interval for different models
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several proatherogenic subfractions, including VLDL, IDL,
and chylomicron remnants. Several studies report that
IDL and small VLDL values, but not LDL value, correlates
with the progression of atherosclerosis [34, 35]. In the
National Heart, Lung, and Blood Institute Type II Coron-
ary Intervention Study, TG-rich lipoproteins were associ-
ated with a faster progression of atherosclerotic lesions
[36]. This previous study reports that the change in IDL at
2 years predicted cardiovascular disease progression at
5 years; this association remained significant after adjust-
ing for treatment assignment. Although the molecular
mechanisms of this association are not fully understood,
they are becoming increasingly clear. Small TG-rich lipo-
proteins can be directly taken up by macrophages to pro-
duce foam cells and are intimately associated with clotting
and the fibrinolytic pathway, thereby contributing to le-
sion progression, plaque rupture, and clinical coronary
events [8, 37]. Our results confirmed that the risk of re-
current MI was highest for patients in the highest non-
HDL quartile.
By contrast, non-HDL was not a significant independent
risk factor for subsequent all-cause mortality. This might be
explained in part because patients with lipoprotein mea-
surements undergoing primary angiography are less sick
than those with surgical contraindications or who died be-
fore lipid measurements could be obtained. In addition, the
nutraceuticals and functional substances contained in food
had already been considered to influence lipids levels be-
yond common clinical treatment [38]. Moreover, the influ-
ences of genetics and environmental factors on the lipid
levels of individuals, the dosage of statin or other prescrip-
tion drug, adherence to therapy and cardiac rehabilitation
participation have important roles on the overall cardiovas-
cular risk [39–41]. Our results are in accord with those of a
previous study that did not detect a relationship between
non-HDL and cardiovascular disease outcomes in a cohort
of patients with prevalent coronary artery disease [42].
However, a recent systematic review of studies, including
patients with multiple risk factors for cardiovascular dis-
ease, found no evidence that non-HDL markers predict the
occurrence of cardiovascular events [43]. Therefore, there
is a need for more research in this field.
Some limitations of this study should be taken into
consideration. First, this is a retrospective analysis of a
Fig. 2 Association between baseline lipid values and incidence of nonfatal recurrent MI. non-HDL, non-high-density lipoprotein; LDL, low-density
lipoprotein; HDL, high-density lipoprotein; TG, triglyceride; CI, confidence interval; OR, odds radio
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consecutive cohort of patients treated with primary
angioplasty from a single center which located in North-
east China and the data may not reflect the general
population of STEMI patients. Other P2Y12 were not
available except for clopidogrel during the study period.
However, patient data were imputed electronically by a
relatively constant group of attending physicians; the
overall strategic management of patients, including PCI
techniques and devices used during the procedure, was
more homogeneous than would be in a multi-centered
study. Second, sudden death that may have been caused
by fatal recurrent MI, and cases of non-symptomatic re-
current MI, may have been overlooked, meaning that
the actual incidence of nonfatal recurrent MI was prob-
ably higher than that observed in our study. However,
these limitations are balanced by our continuous admis-
sion and avoidance of ascertainment bias that occurs in
clinical studies using selected patients. Third, although
we used multivariate models to adjust for covariates, it is
possible that unmeasured confounding variables may
have affected the relationship between lipid values and
the incidence of nonfatal recurrent MI.
Conclusions
To our knowledge, this is the first study to investigate the
relationship between baseline lipid values and nonfatal re-
current MI in patients with STEMI who were treated with
primary PCI. Of all lipid fractions, non-HDL was the stron-
gest predictor of recurrent MI. Moreover, the occurrence of
reinfarction after PCI was highest for patients in the highest
non-HDL quartile.
Additional file
Additional file 1: Table S1. Associations between baseline lipid values
with recurrent MI. (DOC 74 kb)
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